Media Articles Related to Reminyl (Galantamine)
Link between sleep disturbance and amyloid in brain areas affected by Alzheimer's disease
Source: Seniors / Aging News From Medical News Today [2014.12.12]
Healthy, elderly research participants who report being more sleepy and less rested have higher levels of amyloid deposition in regions of the brain that are affected in Alzheimer's disease...
Researchers at Mainz University explore new approach for treating Alzheimer's disease
Source: Neurology / Neuroscience News From Medical News Today [2014.12.09]
It is estimated that about 35 million people worldwide currently suffer from dementia and it is expected that the number will increase to 135 million by the year 2050.
Breakdown in brain connection identified in early Alzheimer's disease
Source: MRI / PET / Ultrasound News From Medical News Today [2014.12.02]
Changes in brain connections visible on MRI could represent an imaging biomarker of Alzheimer's disease, according to a new study presented at the annual meeting of the Radiological Society of North...
Laying siege to beta-amyloid, the key protein in Alzheimer's disease
Source: Huntingtons Disease News From Medical News Today [2014.10.06]
The peptide - a small protein - beta-amyloid is strongly associated with Alzheimer's disease; however, researchers are still looking for unequivocal proof that this peptide is the causal agent of the...
Source: MedicineNet Swallowing Specialty [2014.08.05]
Title: Alzheimer's Disease
Category: Symptoms and Signs
Created: 8/5/2014 2:43:00 PM
Last Editorial Review: 8/5/2014 2:43:52 PM
Published Studies Related to Reminyl (Galantamine)
Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.
Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.
Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. 
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment... Treatment was generally safe and well tolerated.
Galantamine improves sustained attention in chronic cocaine users. 
Chronic cocaine users are known to have cognitive deficits that are predictive of
poor treatment response. Whether these deficits improve with medications
targeting specific cognitive functions has not been examined in previous studies.
Clinical Trials Related to Reminyl (Galantamine)
The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat
problems with thinking and memory caused by electroconvulsive therapy (ECT).
A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYLŪ) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine
hydrobromide (REMINYLŪ) in patients with Alzheimer's disease who have not received or have
not responded to treatment with medication similar to galantamine hydrobromide (REMINYLŪ).
A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is
to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and
Galantamine Effects on Cognitive Function in Marijuana Users [Recruiting]
To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine,
an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease.
Current marijuana users show impaired cognitive functioning, which predicts poor treatment
response to behavioral treatments in this population. Whether cognitive impairment in
marijuana users will improve with medication treatment has not been evaluated. We
hypothesize that galantamine, compared to placebo, will improve cognitive performance in
marijuana users. Galantamine, compared to placebo, will improve working memory, verbal
learning/memory and response inhibition functions in marijuana users.
Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder [Recruiting]
This study will examine whether extended release galantamine, a drug approved by the Food
and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease,
can perform the same function in stable people with bipolar disorder.